8-K: Claritev Reports Strong Q4, FY25 Results; Initiates Share Buyback

Claritev Corporation announced robust fourth quarter and full-year 2025 financial results, including a return to revenue growth and improved profitability, alongside the approval of a new $75 million share repurchase program.

Summary

• Claritev Corporation reported Q4 2025 revenues of $246.6 million, a 6.2% increase from Q4 2024, and a net loss of $80.6 million, a significant improvement from the $138.0 million net loss in Q4 2024.
• Full-year 2025 revenues reached $965.4 million, up 3.7% from FY 2024, with a net loss of $284.3 million, substantially better than the $1,645.8 million net loss in FY 2024.
• Adjusted EBITDA for Q4 2025 was $151.3 million (61.4% margin), and for the full year 2025 was $602.6 million, an increase of 4.5% compared to FY 2024.
• The company achieved positive free cash flow of $36.4 million in Q4 2025, a notable turnaround from $(63.8) million in Q4 2024, though full-year 2025 free cash flow remained negative at $(12.3) million.
• Claritev's Board of Directors approved a five-year share repurchase program, authorizing the purchase of up to $75.0 million of Class A common stock, with a $20.0 million limit per calendar year, effective January 1, 2026, through December 31, 2030.
• For full-year 2026, Claritev initiated guidance projecting revenues between $980 million and $1 billion, Adjusted EBITDA between $605 million and $615 million, and a return to positive free cash flow of $0 million to $10 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong Q4 performance, significant improvement in net loss, a return to revenue growth, and positive free cash flow guidance for 2026. The share repurchase program further enhances shareholder value, despite the company still reporting a full-year net loss for 2025.

Positives

• Q4 2025 revenues increased by 6.2% to $246.6 million compared to Q4 2024.
• Net loss significantly improved in Q4 2025 to $80.6 million from $138.0 million in Q4 2024.
• Adjusted EBITDA grew by 7.0% in Q4 2025 to $151.3 million, with a strong margin of 61.4%.
• The company achieved positive free cash flow of $36.4 million in Q4 2025, a substantial improvement from negative free cash flow in Q4 2024.
• Full-year 2025 revenues increased by 3.7% to $965.4 million compared to FY 2024.
• Full-year 2025 net loss dramatically improved to $284.3 million from $1,645.8 million in FY 2024.
• Full-year 2025 Adjusted EBITDA increased by 4.5% to $602.6 million.
• Management expects a return to positive free cash flow in 2026, with guidance of $0 million to $10 million.
• The Board approved a $75.0 million, five-year share repurchase program, signaling confidence in future performance and commitment to shareholder returns.

Negatives

• The company reported a net loss of $80.6 million for Q4 2025 and $284.3 million for the full year 2025.
• Free cash flow for the full year 2025 remained negative at $(12.3) million, slightly worse than $(10.5) million in FY 2024.
• Unrestricted cash and cash equivalents on the balance sheet at Q4 2025 were $16.8 million, indicating limited liquidity without considering restricted cash.

Risks

• Loss of clients, particularly the largest clients, could materially impact results.
• Inability to achieve the goals of strategic plans and recognize anticipated benefits when expected.
• Challenges in entering new lines of business and broadening the scope of solutions.
• Adverse trends in the U.S. healthcare system, including reduced healthcare utilization and increased patient financial responsibility.
• Effects of competition and pricing pressure in the market.
• Inability of clients to pay for solutions and services.
• Changes in the industry and industry standards and technology.
• Adverse outcomes related to litigation or governmental proceedings.
• Interruptions or security breaches of information technology systems and other cybersecurity attacks.
• Inability to maintain licenses or rights of use for essential software.
• Challenges in protecting proprietary information, processes, and applications.
• Inability to expand network infrastructure.
• Inability to preserve or increase existing market share or the size of preferred provider organization networks.
• Decreases in discounts from providers.
• Pressure to limit access to preferred provider networks.
• Changes in the regulatory environment, including healthcare law and regulations, and the expansion of privacy and security laws.
• Heightened enforcement activity by government agencies.
• Ability to obtain additional financing.
• Ability to pay interest and principal on notes and other indebtedness.
• Lowering or withdrawal of credit ratings.
• Changes in accounting principles or the incurrence of impairment charges.
• Adverse effects from other political, economic, business, and/or competitive factors.

Future Outlook

Claritev has initiated full-year 2026 guidance, projecting revenues between $980 million and $1 billion, Adjusted EBITDA between $605 million and $615 million, and a return to positive free cash flow ranging from $0 million to $10 million. Management expresses confidence in carrying momentum from strong 2025 results into 2026, emphasizing a sustainable growth model, expansion opportunities, and a growing pipeline, with a focus on organic growth, opportunistic debt reduction, and value-creating M&A.

Management Comments

• Travis Dalton, Chairman, CEO and President, stated, "The Year of the Turn was an unqualified success, and we are well on our way to delivering on our theme of 2026 as The Way Up."
• Mr. Dalton also noted that the company's focus on Clarity, Alignment, and Focus, applied against Vision 2030, has allowed them to "turn to profitable growth sooner than expected."
• Doug Garis, CFO, commented, "We are carrying the momentum from our strong fourth quarter and full year results into 2026. Our guidance reflects a sustainable growth model, built on a durable core business foundation, exciting expansion opportunities, and a growing pipeline across our solutions and markets."
• Mr. Garis highlighted the expectation to "return to positive free cash flow in 2026, allowing Claritev to focus on our primary capital allocation priorities of driving organic growth, opportunistic debt reduction, and value-creating M&A."

Industry Context

StockSavvy.ai notes that Claritev's focus on making healthcare more affordable, transparent, and fair, utilizing technology and AI solutions, aligns with broader industry trends emphasizing value-based care, cost containment, and digital transformation in the U.S. healthcare system. The company's reported success in identifying significant medical cost savings ($25.0 billion in FY 2025) demonstrates its relevance in a market continually seeking efficiency and reduced expenditures.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from the approved $75.0 million share repurchase program, which can enhance shareholder value and potentially increase earnings per share.
• Investors/Analysts: Provided with detailed financial results for Q4 and FY 2025, along with 2026 guidance, enabling informed investment decisions and analysis.
• Clients (Payers, Employers, Patients, Providers): Continue to benefit from Claritev's solutions focused on affordability, transparency, and quality in healthcare, with identified potential medical cost savings of $25.0 billion in FY 2025.
• Employees: Management comments highlight the team's pivotal work in 2025, suggesting a positive internal environment and focus on talent alignment.

Next Steps

• Host a conference call on February 23, 2026, at 4:30 p.m. ET to discuss financial results.
• Execute on the 2026 financial guidance, aiming for revenues of $980 million to $1 billion and positive free cash flow of $0 million to $10 million.
• Implement the approved share repurchase program, purchasing up to $75.0 million of Class A common stock through December 31, 2030, with an annual limit of $20.0 million.
• Continue driving organic growth, pursuing opportunistic debt reduction, and engaging in value-creating M&A as primary capital allocation priorities.

Key Dates

Recommendation

Claritev's strong Q4 2025 performance, significant reduction in net loss for the full year, and a return to revenue growth indicate a positive operational turnaround. The 2026 guidance for positive free cash flow and the initiation of a $75 million share repurchase program signal management's confidence and commitment to shareholder value. While the company still reported a full-year net loss, the trajectory of improvement and strategic initiatives make it an attractive 'buy' for investors looking for growth in the healthcare technology sector.

Keywords

Healthcare Technology, Financial Results, Share Repurchase Program, Adjusted EBITDA, Free Cash Flow, Revenue Growth, SEC Filing, Corporate Governance, CTEV